推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 23日，草甘膦原藥市場(chǎng)繼續(xù)弱勢(shì)平穩(wěn)發(fā)展。1月將過(guò)，國(guó)內(nèi)草甘膦原藥市場(chǎng)依然沒(méi)有起色，特別是需求市場(chǎng)，國(guó)內(nèi)、國(guó)外雙方面的詢單都非常少，導(dǎo)致目前大部分草甘膦原藥生產(chǎn)企業(yè)面臨很大的庫(kù)存壓力，春節(jié)前想消化部分庫(kù)存，企業(yè)還需要想別的辦法。即使在這樣的市場(chǎng)條件下，仍然有企業(yè)在繼續(xù)擴(kuò)產(chǎn)。
近期，騰龍的內(nèi)蒙古草甘膦原藥生產(chǎn)線已經(jīng)安裝完畢，每年又有2萬(wàn)～3萬(wàn)噸產(chǎn)能進(jìn)入現(xiàn)在本來(lái)就已經(jīng)競(jìng)爭(zhēng)激烈的市場(chǎng)。與此同時(shí)，國(guó)內(nèi)還有很多企業(yè)在擴(kuò)產(chǎn)，國(guó)內(nèi)整個(gè)草甘膦原藥生產(chǎn)已經(jīng)開(kāi)始脫離市場(chǎng)供需關(guān)系，全面進(jìn)入企業(yè)生產(chǎn)的主導(dǎo)時(shí)期。而今年又面臨孟山都北美工廠的擴(kuò)產(chǎn)，草甘膦行業(yè)已經(jīng)連續(xù)4個(gè)多月一直在低價(jià)格、低成交量上徘徊。照目前的這種情況，開(kāi)春后，草甘膦雖然會(huì)迎來(lái)一段時(shí)間的春天，但是供嚴(yán)重大于求的局面短期內(nèi)是不可能改變的，到時(shí)各企業(yè)忙著降低庫(kù)存壓力，草甘膦原藥價(jià)格將繼續(xù)下降，后市令人擔(dān)憂。
